Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Dec;35(12):2558–2561. doi: 10.1128/aac.35.12.2558

High-pressure liquid chromatography and microbiological assay of serum ofloxacin levels in adults receiving intravenous and oral therapy for skin infections.

G M Auten 1, L C Preheim 1, M Sookpranee 1, M J Bittner 1, T Sookpranee 1, A Vibhagool 1
PMCID: PMC245430  PMID: 1810189

Abstract

Thirty-two adults hospitalized with skin and skin structure infections received intravenous ofloxacin followed by oral ofloxacin. The standard treatment was 400 mg every 12 h. One patient with renal failure received 400 mg every 24 h. Serum ofloxacin levels were measured (1.5 h postdose and 1 h predose) during intravenous (32 patients) and oral (30 patients) therapy. Levels were assayed by high-pressure liquid chromatography (HPLC) and microbiological assay (MBA). Mean levels +/- standard deviation (in micrograms per milliliter) when measured by MBA after intravenous dosing were (postdose versus predose) 6.23 +/- 2.49 versus 2.42 +/- 1.56, and those after oral dosing were 6.17 +/- 3.25 versus 3.49 +/- 2.77. When measured by HPLC, mean levels +/- standard deviation after intravenous dosing were 5.81 +/- 2.08 versus 2.14 +/- 1.26 and those after oral dosing were 5.63 +/- 2.92 versus 3.41 +/- 2.98. There were no significant differences between levels achieved with oral or intravenous dosing when measured by either MBA or HPLC. Levels in serum did not correlate with side effects. The MICs for 50 and 90% of the 40 aerobic pathogens isolated from 21 patients were 0.5 and 2.0 micrograms/ml, respectively. Cure or improvement was achieved in 30 patients. Intravenous and oral administration of ofloxacin yielded similar levels in serum which were safe and effective in the therapy of skin infections in adult patients.

Full text

PDF
2558

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Thornsberry C., Jones R. N. In vitro evaluation of A-56619 and A-56620, two new quinolones. Antimicrob Agents Chemother. 1986 Jan;29(1):40–43. doi: 10.1128/aac.29.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bitar N., Claes R., Van der Auwera P. Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally. Antimicrob Agents Chemother. 1989 Oct;33(10):1686–1690. doi: 10.1128/aac.33.10.1686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chan M. K., Chau P. Y., Chan W. W. Oral treatment of peritonitis in CAPD patients with two dosage regimens of ofloxacin. J Antimicrob Chemother. 1988 Sep;22(3):371–375. doi: 10.1093/jac/22.3.371. [DOI] [PubMed] [Google Scholar]
  5. Farinotti R., Trouvin J. H., Bocquet V., Vermerie N., Carbon C. Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects. Antimicrob Agents Chemother. 1988 Oct;32(10):1590–1592. doi: 10.1128/aac.32.10.1590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Flor S. Pharmacokinetics of ofloxacin. An overview. Am J Med. 1989 Dec 29;87(6C):24S–30S. [PubMed] [Google Scholar]
  7. Gentry L. O., Rodriguez-Gomez G., Zeluff B. J., Khoshdel A., Price M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med. 1989 Dec 29;87(6C):57S–60S. [PubMed] [Google Scholar]
  8. Hook E. W., 3rd, Hooton T. M., Horton C. A., Coyle M. B., Ramsey P. G., Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med. 1986 Feb;146(2):295–297. [PubMed] [Google Scholar]
  9. King A., Shannon K., Phillips I. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin. J Antimicrob Chemother. 1985 May;15(5):551–558. doi: 10.1093/jac/15.5.551. [DOI] [PubMed] [Google Scholar]
  10. Lam W. K., Chau P. Y., So S. Y., Leung Y. K., Chan J. C., Ip M., Sham M. K. Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis. Respir Med. 1989 Jul;83(4):299–303. doi: 10.1016/s0954-6111(89)80200-8. [DOI] [PubMed] [Google Scholar]
  11. Latrive J. P., Barbare J. C., Darchis J. P., Farinotti R., Noel F. Diffusion de l'ofloxacine dans l'ascite infectée. Pathol Biol (Paris) 1989 Jun;37(5 Pt 2):635–637. [PubMed] [Google Scholar]
  12. Lode H., Höffken G., Olschewski P., Sievers B., Kirch A., Borner K., Koeppe P. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother. 1987 Sep;31(9):1338–1342. doi: 10.1128/aac.31.9.1338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Outman W. R., Nightingale C. H. Metabolism and the fluoroquinolones. Am J Med. 1989 Dec 29;87(6C):37S–42S. [PubMed] [Google Scholar]
  14. Pederzoli P., Falconi M., Bassi C., Girelli R., Vesentini S., Martini N., Messori A. Ofloxacin penetration into bile and pancreatic juice. J Antimicrob Chemother. 1989 May;23(5):805–807. doi: 10.1093/jac/23.5.805. [DOI] [PubMed] [Google Scholar]
  15. Pioget J. C., Wolff M., Singlas E., Laisne M. J., Clair B., Regnier B., Vachon F. Diffusion of ofloxacin into cerebrospinal fluid of patients with purulent meningitis or ventriculitis. Antimicrob Agents Chemother. 1989 Jun;33(6):933–936. doi: 10.1128/aac.33.6.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Symonds J., Javaid A., Bone M., Turner A. The penetration of ofloxacin into bronchial secretions. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):91–95. doi: 10.1093/jac/22.supplement_c.91. [DOI] [PubMed] [Google Scholar]
  17. Van Landuyt H. W., Gordts B., D'Hondt G. Pharmacokinetic evaluation of ofloxacin in serum and tonsils. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):81–83. doi: 10.1093/jac/22.supplement_c.81. [DOI] [PubMed] [Google Scholar]
  18. Wijnands W. J., Vree T. B., Baars A. M., Hafkenscheid J. C., Kohler B. E., van Herwaarden C. L. The penetration of ofloxacin into lung tissue. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):85–89. doi: 10.1093/jac/22.supplement_c.85. [DOI] [PubMed] [Google Scholar]
  19. Yew W. W., Kwan S. Y., Ma W. K., Khin M. A., Mok C. K. Single daily-dose ofloxacin monotherapy for Mycobacterium fortuitum sternotomy infection. Chest. 1989 Nov;96(5):1150–1152. doi: 10.1378/chest.96.5.1150. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES